Literature DB >> 20486718

Quantitative proteomic profiling studies of pancreatic cancer stem cells.

Lan Dai1, Chen Li, Kerby A Shedden, Cheong J Lee, Chenwei Li, HuyVuong Quoc, Diane M Simeone, David M Lubman.   

Abstract

Analyzing subpopulations of tumor cells in tissue is a challenging subject in proteomic studies. Pancreatic cancer stem cells (CSCs) are such a group of cells that only constitute 0.2-0.8% of the total tumor cells but have been found to be the origin of pancreatic cancer carcinogenesis and metastasis. Global proteome profiling of pancreatic CSCs from xenograft tumors in mice is a promising way to unveil the molecular machinery underlying the signaling pathways. However, the extremely low availability of pancreatic tissue CSCs (around 10,000 cells per xenograft tumor or patient sample) has limited the utilization of currently standard proteomic approaches which do not work effectively with such a small amount of material. Herein, we describe the profiling of the proteome of pancreatic CSCs using a capillary scale shotgun technique by coupling offline capillary isoelectric focusing(cIEF) with nano reversed phase liquid chromatography(RPLC) followed by spectral counting peptide quantification. A whole cell lysate from 10,000 cells which corresponds to approximately 1 microg of protein material is equally divided for three repeated cIEF separations where around 300 ng of peptide material is used in each run. In comparison with a nontumorigenic tumor cell sample, among 1159 distinct proteins identified with FDR less than 0.2%, 169 differentially expressed proteins are identified after multiple testing corrections where 24% of the proteins are upregulated in the CSCs group. Ingenuity Pathway analysis of these differential expression signatures further suggests significant involvement of signaling pathways related to apoptosis, cell proliferation, inflammation, and metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486718      PMCID: PMC2906393          DOI: 10.1021/pr100231m

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  24 in total

Review 1.  Mitochondria: releasing power for life and unleashing the machineries of death.

Authors:  Donald D Newmeyer; Shelagh Ferguson-Miller
Journal:  Cell       Date:  2003-02-21       Impact factor: 41.582

2.  Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death.

Authors:  N Joza; S A Susin; E Daugas; W L Stanford; S K Cho; C Y Li; T Sasaki; A J Elia; H Y Cheng; L Ravagnan; K F Ferri; N Zamzami; A Wakeham; R Hakem; H Yoshida; Y Y Kong; T W Mak; J C Zúñiga-Pflücker; G Kroemer; J M Penninger
Journal:  Nature       Date:  2001-03-29       Impact factor: 49.962

3.  Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae.

Authors:  Boris Zybailov; Amber L Mosley; Mihaela E Sardiu; Michael K Coleman; Laurence Florens; Michael P Washburn
Journal:  J Proteome Res       Date:  2006-09       Impact factor: 4.466

4.  Comparison of label-free methods for quantifying human proteins by shotgun proteomics.

Authors:  William M Old; Karen Meyer-Arendt; Lauren Aveline-Wolf; Kevin G Pierce; Alex Mendoza; Joel R Sevinsky; Katheryn A Resing; Natalie G Ahn
Journal:  Mol Cell Proteomics       Date:  2005-06-23       Impact factor: 5.911

5.  Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues.

Authors:  S-I Hwang; J Thumar; D H Lundgren; K Rezaul; V Mayya; L Wu; J Eng; M E Wright; D K Han
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

6.  Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis.

Authors:  Moritz N Wente; Michael P Keane; Marie D Burdick; Helmut Friess; Markus W Büchler; Güralp O Ceyhan; Howard A Reber; Robert M Strieter; Oscar J Hines
Journal:  Cancer Lett       Date:  2006-02-03       Impact factor: 8.679

7.  Comparison of multidimensional shotgun technologies targeting tissue proteomics.

Authors:  Xueping Fang; Brian M Balgley; Weijie Wang; Deric M Park; Cheng S Lee
Journal:  Electrophoresis       Date:  2009-12       Impact factor: 3.535

8.  Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.

Authors:  Donna E Hansel; Ayman Rahman; Michael House; Raheela Ashfaq; Karin Berg; Charles J Yeo; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

9.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.

Authors:  Carmen Guerra; Alberto J Schuhmacher; Marta Cañamero; Paul J Grippo; Lena Verdaguer; Lucía Pérez-Gallego; Pierre Dubus; Eric P Sandgren; Mariano Barbacid
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

View more
  20 in total

1.  Dose-dependent proteomic analysis of glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor.

Authors:  Lan Dai; Jintang He; Yashu Liu; Jaeman Byun; Anuradha Vivekanandan; Subramaniam Pennathur; Xing Fan; David M Lubman
Journal:  Proteomics       Date:  2011-10-24       Impact factor: 3.984

Review 2.  Protein analysis by shotgun/bottom-up proteomics.

Authors:  Yaoyang Zhang; Bryan R Fonslow; Bing Shan; Moon-Chang Baek; John R Yates
Journal:  Chem Rev       Date:  2013-02-26       Impact factor: 60.622

3.  Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery.

Authors:  Robert Cunningham; Di Ma; Lingjun Li
Journal:  Front Biol (Beijing)       Date:  2012-08-01

Review 4.  Proteome-based biomarkers in pancreatic cancer.

Authors:  Chen Sun; Ann H Rosendahl; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

5.  Differential profiling studies of N-linked glycoproteins in glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor.

Authors:  Lan Dai; Yashu Liu; Jintang He; Callie G Flack; Caroline E Talsma; Jessica G Crowley; Karin M Muraszko; Xing Fan; David M Lubman
Journal:  Proteomics       Date:  2011-09-08       Impact factor: 3.984

6.  Discrimination of colon cancer stem cells using noncanonical amino acid.

Authors:  Xinrui Duan; Honglin Li; Hexin Chen; Qian Wang
Journal:  Chem Commun (Camb)       Date:  2012-07-30       Impact factor: 6.222

7.  Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells.

Authors:  Kshama R Jaiswal; Hong-Wu Xin; Andrew Anderson; Gordon Wiegand; Bo Kim; Tyler Miller; Danielle Hari; Satyajit Ray; Tomotake Koizumi; Udo Rudloff; Snorri S Thorgeirsson; Itzhak Avital
Journal:  Stem Cell Res       Date:  2012-08-19       Impact factor: 2.020

Review 8.  Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges.

Authors:  Sheng Pan; Teresa A Brentnall; Kimberly Kelly; Ru Chen
Journal:  Proteomics       Date:  2013-01-07       Impact factor: 3.984

9.  Integrated lipidomics and proteomics reveal cardiolipin alterations, upregulation of HADHA and long chain fatty acids in pancreatic cancer stem cells.

Authors:  Claudia Di Carlo; Bebiana C Sousa; Marcello Manfredi; Jessica Brandi; Elisa Dalla Pozza; Emilio Marengo; Marta Palmieri; Ilaria Dando; Michael J O Wakelam; Andrea F Lopez-Clavijo; Daniela Cecconi
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

10.  Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome.

Authors:  Hiroko Kozuka-Hata; Yukiko Nasu-Nishimura; Ryo Koyama-Nasu; Hiroko Ao-Kondo; Kouhei Tsumoto; Tetsu Akiyama; Masaaki Oyama
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.